CDH18

Across TCGA pan-cancer cohorts, CDH18 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDH18 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CDH18 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CDH18 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, KICH, and SCLC are the cancer types where CDH18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.928	0.434	.016	26	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SCLC	OS	Median	IV	0.137	0.556	.025	6	view →
COAD	OS	Median	II,III,IV	0.605	0.860	.007	6	view →
LUAD	OS	Median	All	0.138	0.391	.013	5	view →
ESCA	DFS	Median	All	0.256	0.539	.044	3	view →
SKCM	OS	Median	IV	0.179	0.727	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDH18–UCEC (DFS)

Open the UCEC breakdown →